ASTELLAS-2138-CL-0101
Phase I
OPEN TO ACCRUAL
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
COMPUGEN-CPG-02-101
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
ELICIO-ELI-002-201
Phase I/II
OPEN TO ACCRUAL
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Solid Tumors
EXELIXIS-XL092-002
Phase I
OPEN TO ACCRUAL
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
HELIX-LDOS006
Phase I/II
OPEN TO ACCRUAL
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
IIT-GORE-REDIRICT
Phase II
OPEN TO ACCRUAL
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
MABSPACE-TST001-1001
Phase I/II
OPEN TO ACCRUAL
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors
MERCK-MK1084-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors
MIRATI-1719-001
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
TAKEDA-TAK-280-1501
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer
TVARDI-TVD-101-001H
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
XENCOR-XMAB808-01
Phase I
OPEN TO ACCRUAL
A Phase 1, First-in-human (FIH), Dose-finding and Expansion Study to Evaluate the Safety and Tolerability of XmAb808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
XILIO-XTX301-01-02-001
Phase I
OPEN TO ACCRUAL
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors